http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2745774-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6ae06011d1b958d87f38988ff12bf61 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 |
| filingDate | 2020-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcbe02c23a8910ee307f8eab80c3be3f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b02dfdc27b167635a1ca70c5067cefea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a03aad074d37c4264ec7fd6b8134465e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3b75c5779a914fa37d23d7a57e680a7 |
| publicationDate | 2021-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2745774-C1 |
| titleOfInvention | Method for treatment of patients with new coronavirus infection (covid-19) |
| abstract | FIELD: medicine, pulmonology.SUBSTANCE: invention relates to medicine, namely to to pulmonology and intensive care, and can be used to treat patients with new coronavirus infection (COVID-19). Said method according to the invention includes the diagnosis of infection by obtaining a positive test for the presence of RNA or IgM to SARS-CoV-2 or typical X-ray picture on a computed tomography of the thoracic organs. Then the patient is additionally prescribed acetylsalicylic acid 300 mg on the first day and 150 mg on days 2-21 of illness, clopidogrel 300 mg on the first day and 75 mg on days 2-21 and rivaroxaban 20 mg on days 1-21.EFFECT: use of the invention ensures an effective treatment of COVID-19 infection in patients of different age groups with minimal side effects.1 cl, 3 ex |
| priorityDate | 2020-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.